Advertisement

Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis

  • S. S. Jossan
  • J. Ekblom
  • O. Gudjonsson
  • K.-E. Hagbarth
  • S.-M. Aquilonius
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

In this paper we present results from a double blind cross over trial with deprenyl, a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor, in 10 patients suffering from amyotrophic lateral sclerosis. The patients were randomised in such a way that half of the patients started with the active drug and half with the placebo treatment. Each patient was given 10 mg deprenyl (eldepryl, 10 mg tablets) per day for 12 weeks and then placebo for the same length of time. There was a drug free period of 12 weeks between the courses. The neurological status of the patients were evaluated every six weeks by using Norris, spinal and bulbar scores and it was observed that all cases deteriorated in their clinical status during the 36 weeks of the controlled study. MAO-B activity in blood platelets was completely inhibited during treatment with deprenyl. In the preliminary analysis performed so far, no obvious retardation in the progress of the disease could be observed with deprenyl treatment.

Keywords

Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Patient Motor Neuron Disease Blood Platelet Amyotrophic Lateral Sclerosis Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonduelle M (1975) Amyotrophic lateral sclerosis. In: Vinken PJ, Bruyn GW (eds) Handbook of neurology, vol 22. Elsevier, Amsterdam, pp 281–338.Google Scholar
  2. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578.PubMedCrossRefGoogle Scholar
  3. Criteria for diagnosis of amyotrophic lateral sclerosis (1990) World Neurology 15: 12.Google Scholar
  4. Konradi C, Svoma E, Jellinger K, Riederer P, Denny R, Thibaults J (1988) Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase B and tyrosinhydroxylase in human post mortem brain stem. Neuroscience 26: 791–801.PubMedCrossRefGoogle Scholar
  5. Plaitakis A, Mandeli J, Yahr MD (1988) Pilot trial of branched chain amino acids in amyotrophic lateral sclerosis. Lancet i: 1015–1018.CrossRefGoogle Scholar
  6. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371.CrossRefGoogle Scholar
  7. Riederer P, Youdim M (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with deprenyl. J Neurochem 46: 1359–1365.PubMedCrossRefGoogle Scholar
  8. Salo PT, Tatton WG (1991) Deprenyl reduces the death of motorneurons caused by axotomy. J Neurosci Res 31: 394–400.CrossRefGoogle Scholar
  9. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • S. S. Jossan
    • 1
  • J. Ekblom
    • 2
  • O. Gudjonsson
    • 2
  • K.-E. Hagbarth
    • 2
  • S.-M. Aquilonius
    • 2
  1. 1.Department of Medical PharmacologyUppsala UniversityUppsalaSweden
  2. 2.NeurologyUppsala UniversityUppsalaSweden

Personalised recommendations